The 9th Consortium meeting of TransBioLine took place on the 23rd and 24th of September in London. This two-days hybrid meeting gathered 32 Consortium members together onsite, including 2 members of the SAB, Elmer Schabel [...]
The 8th TransBioLine Consortium meeting took place in Sitges (Barcelona) on the 11th and 12th of April 2024. This 2-days hybrid meeting of the Consortium members included updates on all the organ Work Packages, discussions on project sustainability [...]
The TransBioLine consortium has been working for the past five years on discovery, validation and regulatory qualification of a variety of safety biomarkers for drug-induced organ injury. On Friday, February 9, 2024, the first Biomarker [...]
At the beginning of October, more than 40 members of TransBioLine participated in the 7th Consortium Meeting hosted by Roche in Basel (Switzerland). Only 15 months left until the project end, the main focus of [...]
During year 4, huge progress has been done in the enrolment of patients in the clinical studies within the TransBioLine project to move forward in the identification of novel biomarkers that reliably indicate specific organ [...]
We are delighted to announce that the TransBioLine Newsletter Year 4 is online! This Newsletter summarizes the highlights of the scientific progress and the consortium activities during the fourth year of the project. Don’t want [...]
TransBioLine work package 3 (WP3; drug-induced pancreatic injury; DIPI) applauds the recent Letter of Support issued by the FDA for DIPI safety biomarkers to the Critical Path Institute’s Predictive Safety Testing Consortium (PSTC). Within the [...]
We are delighted to announce that the TransBioLine Newsletter Year 3 is online! This Newsletter summarizes the highlights of the scientific progress and the consortium activities during the third year of the project. Don’t want [...]
During year 3, clinical studies within the TransBioLine project are progressing in the enrolment of patients to move forward in the identification of novel biomarkers that reliably indicate specific organ injury during drug development. Status [...]
